Context: Circulating microRNAs (miRNAs/miRs) are used as novel biomarkers for diseases. miR-21, miR-126, and miR-210 are known to be deregulated in vivo or in vitro under diabetic conditions.
Objective: The aim of this study was to investigate the circulating miR-21, miR-126, and miR-210 in plasma and urine from pediatric patients with type 1 diabetes and to link our findings to cardiovascular and diabetic nephropathy risk factors in children with type 1 diabetes.
Design: miR-21, miR-126, and miR-210 concentrations were measured with quantitative RT-PCR in plasma and urine samples from 68 pediatric patients with type 1 diabetes and 79 sex- and age-matched controls.
Setting: The study consisted of clinical pediatric patients with type 1 diabetes.
Patients Or Other Participants: Inclusion criterion for patients was diagnosed type 1 diabetes. Exclusion criteria were febrile illness during the last 3 months; chronic inflammatory or rheumatic disease; hepatitis; HIV; glucocorticoid treatment; liver, renal, or cardiac failure; or hereditary dyslipidemia. Patients were age and sex matched to controls.
Main Outcome Measure(s): Main outcome parameters were changes in miR-21, miR-126, and miR-210 concentration in plasma and urine from type 1 diabetic patients compared with corresponding controls.
Results: Circulating miRNA levels of miR-21 and miR-210 were significantly up-regulated in the plasma and urine of the type 1 diabetic patients. Urinary miR-126 levels in diabetic patients were significantly lower than in age- and gender-matched controls and negatively correlated between the patient's glycated hemoglobin mean and miR-126 concentration value. In contrast, circulating miR-126 levels in plasma were comparable in both cohorts. For urinary miR-21, we found by an adjusted receiver-operating characteristic-curve analysis with an area under the curve of 0.78.
Conclusions: Type 1 diabetic pediatric patients revealed a significant deregulation of miR-21, miR-126, and miR-210 in plasma and urinary samples, which might indicate an early onset of diabetic-associated diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/jc.2013-3868 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pediatric Dialysis: Ethical Dilemmas Faced by Pediatric Intensive Care Nurses.
Nephrol Nurs J
January 2025
Research Associate Professor of Biostatistics, Department of Biostatics and Computational Biology, University of Rochester Medical Center, Rochester, NY.
Whether pediatric dialysis is morally obligatory is an ethical issue. The study's aim was to understand neonatal and pediatric intensive care unit (ICU) nurses' beliefs regarding the ethical use of pediatric dialysis. A single center study was conducted using theoretical and case-based surveys.
View Article and Find Full Text PDFThrombotic Microangiopathy Associated with Systemic Adeno-Associated Virus Gene Transfer: Review of Reported Cases.
Hum Gene Ther
January 2025
BridgeBio Gene Therapy, Palo Alto, California, USA.
Complement-mediated thrombotic microangiopathy (TMA) in the form of atypical hemolytic uremic syndrome (aHUS) has emerged as an immune complication of systemic adeno-associated virus (AAV) gene transfer that was unforeseen based on nonclinical studies. Understanding this phenomenon in the clinical setting has been limited by incomplete data and a lack of uniform diagnostic and reporting criteria. While apparently rare based on available information, AAV-associated TMA/aHUS can pose a substantial risk to patients including one published fatality.
View Article and Find Full Text PDFPEGylated Granulocyte Colony-Stimulating Factor and Plerixafor Enhance Autologous Stem and Progenitor Cell Mobilization and Transplantation in Pediatric Patients.
Stem Cells Dev
January 2025
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Autologous hematopoietic stem cell transplantation is used to restore bone marrow function after high-dose chemotherapy. For apheresis, granulocyte colony-stimulating factor (G-CSF) is standard of care, but obtaining sufficient stem cells can be challenging. Other mobilization agents include plerixafor and PEGylated G-CSF (PEG-G-CSF).
View Article and Find Full Text PDFLeveraging eCAP thresholds in a logistic model to predict speech outcomes after implantation in anomalous cochlea.
Acta Otolaryngol
January 2025
Neuro-Otology, Department of Neurosurgery, SGPGIMS, Lucknow, Uttar Pradesh, India.
Background: Pediatric cochlear implant (CI) recipients with cochlear malformations face challenges due to variable speech recognition outcomes.
Aims/objectives: This study assesses the predictive value of intraoperative electrically evoked compound action potential (eCAP) thresholds, residual hearing, age at implantation, Intelligent Quotient (IQ), and malformation type for speech recognition outcomes.
Material And Methods: A prospective cohort of 52 children (aged 1-4 years) with cochlear malformations who underwent CI between 2016 and 2024 was analyzed.
Self-inflicted oral-dental mutilations (SIODMs) in paediatric patients: a systematic review of case reports and case series.
Eur J Paediatr Dent
January 2025
Dentistry Unit, AORN Santobono-Pausilipon Pediatric Hospital, 80129 Naples, Italy.
Aim: Self-inflicted oral-dental mutilations (SIODMs) are the result of an intentional or unintentional action that leads to anatomical and functional damage to the soft and hard tissues of the oral cavity. In paediatric patients they can be associated with both organic and functional diseases. A systematic review was conducted aiming to consolidate and integrate the existing knowledge on SIODM in paediatric patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!